New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
19:19 EDTLLYEli Lilly, BIPI announce results of two Phase lll clinical trials
Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes, T2D, Boehringer Ingelheim Pharmaceuticals, BIPI, and Eli Lilly and Company announced. The findings were presented as late breaking abstracts at the American Diabetes Association 74th Scientific Sessions. The 24-week primary findings of these two 52-week trials compared the combination of empagliflozin and linagliptin with empagliflozin or linagliptin alone in patients with T2D and moderately elevated blood glucose levels consistent with what is often seen in clinical practice.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
14:43 EDTLLYEli Lilly confirms FDA approval of Portrazza
Subscribe for More Information
11:48 EDTLLYFDA approves Portrazza to treat NSCLC
Subscribe for More Information
November 19, 2015
06:34 EDTLLYEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
November 18, 2015
08:11 EDTLLYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
06:09 EDTLLYValeant's Addyi sees hardly any sales, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use